SG10201608747RA - Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence - Google Patents

Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Info

Publication number
SG10201608747RA
SG10201608747RA SG10201608747RA SG10201608747RA SG10201608747RA SG 10201608747R A SG10201608747R A SG 10201608747RA SG 10201608747R A SG10201608747R A SG 10201608747RA SG 10201608747R A SG10201608747R A SG 10201608747RA SG 10201608747R A SG10201608747R A SG 10201608747RA
Authority
SG
Singapore
Prior art keywords
cancer
hemoglobin
prevention
pharmaceutical composition
oxygen carrier
Prior art date
Application number
SG10201608747RA
Other languages
English (en)
Inventor
Bing Lou Wong
Sui Yi Kwok
Sze Hang Lau
Norman Fung Man Wai
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of SG10201608747RA publication Critical patent/SG10201608747RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201608747RA 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence SG10201608747RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712853P 2012-10-12 2012-10-12
US13/713,031 US20140106004A1 (en) 2012-10-12 2012-12-13 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Publications (1)

Publication Number Publication Date
SG10201608747RA true SG10201608747RA (en) 2016-12-29

Family

ID=50475529

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201608747RA SG10201608747RA (en) 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
SG10201607846PA SG10201607846PA (en) 2012-10-12 2013-10-11 Hemoglobin-Based Oxygen Carrier-Containing Pharmaceutical Composition for Cancer Targeting Treatment and Prevention of Cancer Recurrence
SG11201502133SA SG11201502133SA (en) 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201607846PA SG10201607846PA (en) 2012-10-12 2013-10-11 Hemoglobin-Based Oxygen Carrier-Containing Pharmaceutical Composition for Cancer Targeting Treatment and Prevention of Cancer Recurrence
SG11201502133SA SG11201502133SA (en) 2012-10-12 2013-10-11 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Country Status (21)

Country Link
US (2) US20140106004A1 (cg-RX-API-DMAC7.html)
EP (1) EP2906222A4 (cg-RX-API-DMAC7.html)
JP (1) JP6113850B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150065881A (cg-RX-API-DMAC7.html)
CN (1) CN104717966B (cg-RX-API-DMAC7.html)
AP (1) AP2015008315A0 (cg-RX-API-DMAC7.html)
AR (1) AR093023A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013329121B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015007475A2 (cg-RX-API-DMAC7.html)
CA (1) CA2884521C (cg-RX-API-DMAC7.html)
CL (1) CL2015000897A1 (cg-RX-API-DMAC7.html)
EA (1) EA201500301A1 (cg-RX-API-DMAC7.html)
IL (1) IL237763A (cg-RX-API-DMAC7.html)
MA (1) MA37994A2 (cg-RX-API-DMAC7.html)
MX (1) MX367562B (cg-RX-API-DMAC7.html)
PH (1) PH12015500562B1 (cg-RX-API-DMAC7.html)
SG (3) SG10201608747RA (cg-RX-API-DMAC7.html)
TW (1) TW201414489A (cg-RX-API-DMAC7.html)
UY (1) UY35082A (cg-RX-API-DMAC7.html)
WO (1) WO2014059199A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201501949B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911414C (en) * 2013-05-13 2018-09-11 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
CA2952121A1 (en) 2014-06-13 2015-12-17 Childrens' Medical Center Corporation Products and methods to isolate mitochondria
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US20170151287A1 (en) 2015-11-30 2017-06-01 Flagship Ventures Management, Inc. Methods and compositions of chondrisomes
ES3057779T3 (en) * 2016-01-15 2026-03-04 Childrens Medical Ct Corp Therapeutic use of mitochondria and combined mitochondrial agents
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン:癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CU20190106A7 (es) 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
JPWO2019124423A1 (ja) * 2017-12-19 2020-10-22 国立大学法人 岡山大学 がんの進行抑制、治療、予防及び/又は再発予防剤
CN111558032B (zh) * 2020-05-19 2023-08-22 中国科学院宁波材料技术与工程研究所 一种蛋白纳米药物及其制备方法与应用
CN114344263B (zh) * 2022-02-21 2023-08-01 杭州普略生物科技有限公司 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用
KR102793996B1 (ko) 2022-03-31 2025-04-09 충남대학교산학협력단 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물
WO2025222059A1 (en) * 2024-04-17 2025-10-23 Prolong Pharmaceuticals Llc Method of treating cancer using pegylated bovine hemoglobin
CN119746044A (zh) * 2025-03-06 2025-04-04 润方(北京)生物医药研究院有限公司 血红蛋白氧载体在制备抗病毒药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
JP2006508939A (ja) * 2002-10-29 2006-03-16 エンジーン, インコーポレイテッド 癌処置のための組成物
EP2389068A4 (en) * 2009-01-23 2012-07-18 Cancer Rec Tech Ltd HEMGE OF THE HEDGEHOG SIGNAL PATH
DK3266463T3 (da) * 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
WO2011005886A1 (en) * 2009-07-07 2011-01-13 Normoxys, Inc. Method of reducing multi-drug resistance using inositol tripyrophosphate
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) * 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
CA2884521A1 (en) 2014-04-17
TW201414489A (zh) 2014-04-16
CN104717966A (zh) 2015-06-17
EP2906222A1 (en) 2015-08-19
PH12015500562A1 (en) 2015-05-04
SG10201607846PA (en) 2016-11-29
WO2014059199A1 (en) 2014-04-17
ZA201501949B (en) 2016-01-27
JP6113850B2 (ja) 2017-04-12
UY35082A (es) 2014-07-31
CA2884521C (en) 2018-05-01
AU2013329121A1 (en) 2015-04-09
PH12015500562B1 (en) 2015-05-04
IL237763A (en) 2017-07-31
AR093023A1 (es) 2015-05-13
KR20150065881A (ko) 2015-06-15
MA37994A2 (fr) 2016-06-30
CL2015000897A1 (es) 2015-08-21
US9056098B2 (en) 2015-06-16
HK1206281A1 (en) 2016-01-08
BR112015007475A2 (pt) 2017-08-08
EA201500301A1 (ru) 2015-08-31
AU2013329121B2 (en) 2017-05-25
AP2015008315A0 (en) 2015-03-31
US20140106004A1 (en) 2014-04-17
MX367562B (es) 2019-08-27
US20140303085A1 (en) 2014-10-09
CN104717966B (zh) 2018-08-24
MX2015004512A (es) 2015-12-01
EP2906222A4 (en) 2016-06-22
SG11201502133SA (en) 2015-04-29
JP2015534946A (ja) 2015-12-07
WO2014059199A8 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
ZA201501949B (en) Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
HUE046788T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
PL2818482T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
PL2824114T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu
PT2832365T (pt) Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
PT2740489T (pt) Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
PL2740796T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi
HUE039219T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
PL2532743T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
PL2532365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
PT2832366T (pt) Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
PT2716291T (pt) Associação de opióides e fármacos anticancerígenos para o tratamento de cancro
HUE042081T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
PL2532367T3 (pl) Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu
IN2014MN00948A (cg-RX-API-DMAC7.html)
ZA201502695B (en) Stable pharmaceutical composition of peginterferon alpha-2b
IL236321A0 (en) Combined treatment for cancer and immunosuppression
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
GB201100404D0 (en) Combination of metformin and syrosingopine for the treatment of cancer and immunosuppression